WallStreetZenWallStreetZen

NASDAQ: MLTX
Moonlake Immunotherapeutics Stock Forecast, Predictions & Price Target

Analyst price target for MLTX

Based on 8 analysts offering 12 month price targets for Moonlake Immunotherapeutics.
Min Forecast
$62.00+42.07%
Avg Forecast
$77.00+76.44%
Max Forecast
$100.00+129.15%

Should I buy or sell MLTX stock?

Based on 8 analysts offering ratings for Moonlake Immunotherapeutics.
Strong Buy
Strong Buy
4 analysts 50%
Buy
3 analysts 37.5%
Hold
1 analysts 12.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MLTX stock forecasts and price targets.

MLTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-11
lockedlocked$00.00+00.00%2024-04-09
lockedlocked$00.00+00.00%2024-04-02
lockedlocked$00.00+00.00%2024-03-13
lockedlocked$00.00+00.00%2023-12-18
Citigroup
Top 36%
65
Strong BuyInitiates Coverage On$72.00+64.99%2023-12-08
Guggenheim
Top 28%
73
Strong BuyMaintains$77.00+76.44%2023-11-15
Cantor Fitzgerald
Top 13%
88
Strong BuyReiterates$78.00+78.74%2023-11-08

1 of 1

Forecast return on equity

Is MLTX forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36.1%

Forecast return on assets

Is MLTX forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

MLTX revenue forecast

What is MLTX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$90.4M
Avg 2 year Forecast
$554.9M
Avg 3 year Forecast
$1.3B

MLTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MLTX$43.64$77.00+76.44%Strong Buy
ACAD$16.89$30.36+79.78%Buy
IMCR$55.54$80.71+45.33%Buy
MOR$18.02$12.13-32.71%Buy
APGE$53.07$69.67+31.27%Strong Buy

Moonlake Immunotherapeutics Stock Forecast FAQ

Is Moonlake Immunotherapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: MLTX) stock is to Strong Buy MLTX stock.

Out of 8 analysts, 4 (50%) are recommending MLTX as a Strong Buy, 3 (37.5%) are recommending MLTX as a Buy, 1 (12.5%) are recommending MLTX as a Hold, 0 (0%) are recommending MLTX as a Sell, and 0 (0%) are recommending MLTX as a Strong Sell.

If you're new to stock investing, here's how to buy Moonlake Immunotherapeutics stock.

What is MLTX's revenue growth forecast for 2027-2029?

(NASDAQ: MLTX) Moonlake Immunotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.3%.

Moonlake Immunotherapeutics's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast MLTX's revenue for 2027 to be $5,774,723,965, with the lowest MLTX revenue forecast at $5,251,491,425, and the highest MLTX revenue forecast at $6,163,155,448. On average, 3 Wall Street analysts forecast MLTX's revenue for 2028 to be $35,448,844,857, with the lowest MLTX revenue forecast at $17,664,688,311, and the highest MLTX revenue forecast at $45,429,872,903.

In 2029, MLTX is forecast to generate $85,938,548,914 in revenue, with the lowest revenue forecast at $38,280,944,794 and the highest revenue forecast at $123,806,785,258.

What is MLTX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: MLTX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is MLTX's Price Target?

According to 8 Wall Street analysts that have issued a 1 year MLTX price target, the average MLTX price target is $77.00, with the highest MLTX stock price forecast at $100.00 and the lowest MLTX stock price forecast at $62.00.

On average, Wall Street analysts predict that Moonlake Immunotherapeutics's share price could reach $77.00 by Apr 11, 2025. The average Moonlake Immunotherapeutics stock price prediction forecasts a potential upside of 76.44% from the current MLTX share price of $43.64.

What is MLTX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: MLTX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.